<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01695733</url>
  </required_header>
  <id_info>
    <org_study_id>201010722</org_study_id>
    <nct_id>NCT01695733</nct_id>
  </id_info>
  <brief_title>Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy</brief_title>
  <official_title>Influenza Vaccination Response in Patients With Non-Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the best time to administer the influenza vaccine to patients&#xD;
      with non-hematologic malignancies receiving chemotherapy. Giving the vaccine at different&#xD;
      times relative to chemotherapy may affect how well it works to help the body build an immune&#xD;
      response and prevent influenza in these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no longer had funding to continue&#xD;
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal timing of seasonal influenza vaccination with regard to chemotherapy administration schedule.</measure>
    <time_frame>4 weeks from the influenza vaccine</time_frame>
    <description>We will assess co-primary endpoints of serologic response to the H3N2 and H1N1 strains in the 2011-2012 and 2012-2013 seasonal influenza vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Report the presence of post-vaccination adverse events</measure>
    <time_frame>4 weeks from the influenza vaccine</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza vaccination on the first day of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trivalent influenza vaccine</intervention_name>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_label>Schedule B</arm_group_label>
    <other_name>Flushield, Fluvirin, Fluzone, Influenza Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have biopsy-confirmed non-hematological malignancy&#xD;
&#xD;
          -  Patients must be scheduled to receive cytotoxic chemotherapy (adjuvant or metastatic&#xD;
             setting), excluding immunotherapy&#xD;
&#xD;
          -  Patients must be of age &gt;=18 years.&#xD;
&#xD;
          -  Patients must have an absolute lymphocyte count &gt;= 1,000/mcL immediately prior to&#xD;
             influenza vaccination&#xD;
&#xD;
          -  Ability of the patient (or legally authorized representative if applicable) to&#xD;
             understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have already received the influenza vaccine during the season in which&#xD;
             they are considered for eligibility will be excluded&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to the influenza vaccine or egg allergies&#xD;
&#xD;
          -  Previous history of Guillian-Barre syndrome within the previous 6 weeks to influenza&#xD;
             vaccination&#xD;
&#xD;
          -  Patients must not be receiving chronic steroid therapy, defined as &gt;= 14 days, unless&#xD;
             used as part of a chemotherapy regimen&#xD;
&#xD;
          -  Patients must not be on any other agents that can suppress the immune system&#xD;
&#xD;
          -  Planned concurrent therapy with radiation&#xD;
&#xD;
          -  Uncontrolled illness at time of enrollment or influenza vaccination including, but not&#xD;
             limited to, ongoing or active febrile illness&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Known immunosuppression eg. history of organ transplantation or known human&#xD;
             immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy&#xD;
             are ineligible because they may not be able to mount an appropriate immune response&#xD;
&#xD;
          -  History of influenza-like illness, defined as a temperature &gt; 37.8 degree C with cough&#xD;
             or sore throat starting October 1, 2011 throughout the duration of the study&#xD;
&#xD;
          -  Patient may not be scheduled to receive chemotherapy on a weekly basis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saiama Waqar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>September 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2012</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

